|Articles|November 6, 2013

ACT 2014 e-media kit

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Related Content

Moving Beyond Historical Site Data to Real-Time Patient Insight

ByLiz Beatty,Andy Studna, Senior Editor

January 12th 2026

ACT Brief: Trial Competition Slows AI Gains, Rethinking Patient-Level Safety Decisions, and What Separates Real AI Platforms in Clinical Trials

ByAndy Studna, Senior Editor

January 12th 2026

Image Credit: Adobe Stock Images/KHAN VECTOR CO.

Reasoning About Individual Drug Causality in a Multifactorial World

ByEytan Ellenberg, MD, MPH, PhD

January 9th 2026

Why Trial Competition Is Undermining AI-Driven Gains

ByLiz Beatty,Andy Studna, Senior Editor

January 9th 2026

ACT Brief: Recalibrating Trial Efficiency and Access, Verana-COTA Merge to Expand RWE Scale, and FDA Rejects Hetlioz Jet Lag Indication

ByAndy Studna, Senior Editor

January 9th 2026

ACT 2014 e-media kit

Newsletter

Related Content

Moving Beyond Historical Site Data to Real-Time Patient Insight

ACT Brief: Trial Competition Slows AI Gains, Rethinking Patient-Level Safety Decisions, and What Separates Real AI Platforms in Clinical Trials

Reasoning About Individual Drug Causality in a Multifactorial World

Why Trial Competition Is Undermining AI-Driven Gains

ACT Brief: Recalibrating Trial Efficiency and Access, Verana-COTA Merge to Expand RWE Scale, and FDA Rejects Hetlioz Jet Lag Indication

Trending on Applied Clinical Trials Online

Why Trial Competition Is Undermining AI-Driven Gains

Reasoning About Individual Drug Causality in a Multifactorial World

BostonGene Expands AI-Driven Oncology Collaborations with New AstraZeneca Deal

Moving Beyond Historical Site Data to Real-Time Patient Insight

ACT Brief: Recalibrating Trial Efficiency and Access, Verana-COTA Merge to Expand RWE Scale, and FDA Rejects Hetlioz Jet Lag Indication